Table 4 Outcomes of therapy at recommended Phase II dose (dose level 2, n=20 patients)

From: A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Outcome

n

%

Response to therapy

0

0

Completed six cycles of therapy

1

5

Progressive disease in brain

10

50

Progressive disease outside brain

3

15

Toxicity necessitating withdrawal from trial

6

30

Back to article page